Galectin Therapeutics Inc. (GALT)

[biotech2010]

That's impossible because it's a double blind study, no results will be known until all of the data is complete.

Uihlein's sale of 2M shares (80% of his holding) is a true red flag, just as a $30M secondary on the open market that will cause considerable dilution as well as downward pressure on the stock.

I sold my remaining GALT shares earlier this week at $2.80 and while I have some July $4 calls as a hedge believe they will expire worthless.